Azitra (NYSEAMERICAN:AZTR – Get Free Report) will likely be posting its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to post earnings of ($0.1150) per share for the quarter. Parties can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 9:30 AM ET.
Azitra (NYSEAMERICAN:AZTR – Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.24). On average, analysts expect Azitra to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.
Azitra Price Performance
AZTR stock opened at $0.12 on Monday. Azitra has a one year low of $0.10 and a one year high of $1.40. The company’s 50 day moving average price is $0.17 and its two-hundred day moving average price is $0.21.
About Azitra
Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.
The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.
Featured Articles
- Five stocks we like better than Azitra
- 3 Humanoid Robot ETFs to Ride a Speculative Trend
- Bearish Pressure Is Building Around These 3 Stocks
- 3 Low-Volatility Plays Quietly Making a Name For Themselves
- ASML’s Dividend Growth Adds a Quiet Income Angle to Its AI Chip Story
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
